NEC member MorphoSys USA Inc. recently acquired Constellation Pharmaceuticals, Inc., an oncology firm, which increases its presence in Boston. MorphoSys, a biopharmaceutical company that focuses primarily on cancer treatments, launched its headquarters in Boston in 2019 and recently its office grew to 150 people. With this acquisition, the company gained an additional 145 new employees. CEO Jean-Paul Kress has indicated that the company plans to continue growing and expanding in the Boston area.
When asked about the acquisition, Kress said, “We’re extremely pleased to add these people and these competencies to our teams at MorphoSys to accomplish our mission of helping patients with devastating diseases, in hematology oncology especially… We want to preserve and leverage [Constellation’s] expertise in this field of research and development and hopefully commercialization at some point. The plans are being formed right now on how we will set the larger company up for optimal success.”
The New England Council congratulates MorphoSys USA, Inc. for their acquisition and expansion goals. Read more at the Boston Business Journal.
Recently from the Blog
NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022